UA78714C2 - Pharmaceutical composition for treating or preventing diseases involving decreasing and/or impaired cognitive functions - Google Patents

Pharmaceutical composition for treating or preventing diseases involving decreasing and/or impaired cognitive functions Download PDF

Info

Publication number: UA78714C2
Authority: UA; Ukraine
Prior art keywords: diseases; disease; active ingredient; mental retardation; phenyl
Prior art date: 2001-07-18

Application number

UA2004021167A

Other languages

English (en)

Ukrainian (uk)

Inventor

Laszlo Gabor Harsing

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-18

Filing date

2002-07-18

Publication date

2007-04-25

2002-07-18 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2007-04-25 Publication of UA78714C2 publication Critical patent/UA78714C2/uk

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
201000010099 disease Diseases 0.000 title claims abstract description 27
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
230000003920 cognitive function Effects 0.000 title claims abstract description 14
230000001771 impaired effect Effects 0.000 title claims abstract description 5
230000003247 decreasing effect Effects 0.000 title claims abstract 3
150000001875 compounds Chemical class 0.000 claims abstract description 24
239000004480 active ingredient Substances 0.000 claims abstract description 19
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
239000001257 hydrogen Substances 0.000 claims abstract description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
208000023105 Huntington disease Diseases 0.000 claims abstract description 8
208000006264 Korsakoff syndrome Diseases 0.000 claims abstract description 8
208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
230000003340 mental effect Effects 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 27
208000036626 Mental retardation Diseases 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 22
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 15
230000006735 deficit Effects 0.000 claims description 12
230000006806 disease prevention Effects 0.000 claims description 12
208000024827 Alzheimer disease Diseases 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 7
206010012289 Dementia Diseases 0.000 claims description 5
206010039966 Senile dementia Diseases 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
239000012752 auxiliary agent Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000008063 pharmaceutical solvent Substances 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims 4
230000002427 irreversible effect Effects 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
RFQWRWCCNQNACG-HJYQBBATSA-N (e)-but-2-enedioic acid;n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 RFQWRWCCNQNACG-HJYQBBATSA-N 0.000 abstract 1
230000002950 deficient Effects 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 18
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
230000014759 maintenance of location Effects 0.000 description 7
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
241000700159 Rattus Species 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000007704 transition Effects 0.000 description 6
230000000949 anxiolytic effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000007787 long-term memory Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000008298 dragée Substances 0.000 description 4
230000015654 memory Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000004926 polymethyl methacrylate Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000035939 shock Effects 0.000 description 3
230000006403 short-term memory Effects 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical class C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
206010027175 memory impairment Diseases 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000003997 social interaction Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
241000969729 Apteryx rowi Species 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003753 cholecystokinin receptor stimulating agent Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
229960002456 hexobarbital Drugs 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
-1 hydrogen halides Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000028252 learning or memory Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000004579 marble Substances 0.000 description 1
230000005056 memory consolidation Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000012549 training Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2004021167A 2001-07-18 2002-07-18 Pharmaceutical composition for treating or preventing diseases involving decreasing and/or impaired cognitive functions UA78714C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0103017A HUP0103017A3 (en)	2001-07-18	2001-07-18	Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use
PCT/HU2002/000069 WO2003007926A2 (en)	2001-07-18	2002-07-18	Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions

Publications (1)

Publication Number	Publication Date
UA78714C2 true UA78714C2 (en)	2007-04-25

Family

ID=90001562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2004021167A UA78714C2 (en)	2001-07-18	2002-07-18	Pharmaceutical composition for treating or preventing diseases involving decreasing and/or impaired cognitive functions

Country Status (18)

Country	Link
US (1)	US20040171696A1 (cs)
EP (1)	EP1408940B1 (cs)
JP (1)	JP2004537548A (cs)
KR (1)	KR20040017326A (cs)
CN (1)	CN1545410A (cs)
AT (1)	ATE408403T1 (cs)
CA (1)	CA2453834A1 (cs)
CZ (1)	CZ200460A3 (cs)
DE (1)	DE60228968D1 (cs)
EA (1)	EA006897B1 (cs)
HU (1)	HUP0103017A3 (cs)
IL (1)	IL159841A0 (cs)
PL (1)	PL365258A1 (cs)
RS (1)	RS4904A (cs)
SK (1)	SK312004A3 (cs)
UA (1)	UA78714C2 (cs)
WO (1)	WO2003007926A2 (cs)
ZA (1)	ZA200400481B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0301537A3 (en) *	2003-06-03	2005-07-28	Egis Gyogyszergyar Nyilvanosan	Deramcyclane fumarate tablets and process for producing them
HUP0301906A3 (en) *	2003-06-23	2006-03-28	Egis Gyogyszergyar Nyilvanosan	Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity
EP1500391A1 (en) *	2003-07-24	2005-01-26	Neuro3D	Therapeutic use of bicycloheptane derivatives
SK50812006A3 (sk) *	2004-03-12	2007-03-01	Egis Gy�gyszergy�r Nyrt.	Kombinácia deramciklanu a opioidov ako analgetík
CZ2006628A3 (cs) *	2004-03-12	2007-01-24	Egis Gyogyszergyár Nyrt.	Kombinovaná farmaceutická kompozice pro inhibici poklesu kognitivních funkcí
KR101642113B1 (ko)	2014-10-08	2016-07-25	원광대학교산학협력단	퇴행성 뇌질환을 예방, 개선 또는 치료하는 유황의 법제 방법 및 상기 방법으로 법제된 유황
US11478467B2 (en)	2017-05-04	2022-10-25	Sreenivasarao Vepachedu	Targeted drug rescue with novel compositions, combinations, and methods thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU179164B (en) *	1979-12-14	1982-08-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing cycloalkyl-ethers of alkanolamines
HU226061B1 (en) *	1996-10-17	2008-04-28	Egis Gyogyszergyar Nyilvanosan	1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
HU227114B1 (en) *	1999-05-11	2010-07-28	Egis Gyogyszergyar Nyilvanosan	(1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
US6335371B1 (en) *	2000-11-28	2002-01-01	Orion Corporation	Method for inducing cognition enhancement

2001
- 2001-07-18 HU HU0103017A patent/HUP0103017A3/hu unknown
2002
- 2002-07-18 UA UA2004021167A patent/UA78714C2/uk unknown
- 2002-07-18 SK SK31-2004A patent/SK312004A3/sk not_active Application Discontinuation
- 2002-07-18 JP JP2003513535A patent/JP2004537548A/ja active Pending
- 2002-07-18 AT AT02745700T patent/ATE408403T1/de not_active IP Right Cessation
- 2002-07-18 DE DE60228968T patent/DE60228968D1/de not_active Expired - Fee Related
- 2002-07-18 CA CA002453834A patent/CA2453834A1/en not_active Abandoned
- 2002-07-18 IL IL15984102A patent/IL159841A0/xx unknown
- 2002-07-18 PL PL02365258A patent/PL365258A1/xx not_active Application Discontinuation
- 2002-07-18 CZ CZ200460A patent/CZ200460A3/cs unknown
- 2002-07-18 US US10/483,808 patent/US20040171696A1/en not_active Abandoned
- 2002-07-18 KR KR10-2004-7000792A patent/KR20040017326A/ko not_active Abandoned
- 2002-07-18 RS YU4904A patent/RS4904A/sr unknown
- 2002-07-18 WO PCT/HU2002/000069 patent/WO2003007926A2/en not_active Ceased
- 2002-07-18 CN CNA028163729A patent/CN1545410A/zh active Pending
- 2002-07-18 EP EP02745700A patent/EP1408940B1/en not_active Expired - Lifetime
- 2002-07-18 EA EA200400192A patent/EA006897B1/ru not_active IP Right Cessation
2004
- 2004-01-22 ZA ZA200400481A patent/ZA200400481B/en unknown

Also Published As

Publication number	Publication date
SK312004A3 (en)	2004-06-08
WO2003007926A3 (en)	2003-09-18
JP2004537548A (ja)	2004-12-16
EA006897B1 (ru)	2006-04-28
HUP0103017D0 (en)	2001-10-28
CA2453834A1 (en)	2003-01-30
US20040171696A1 (en)	2004-09-02
RS4904A (sr)	2006-10-27
EP1408940B1 (en)	2008-09-17
EP1408940A2 (en)	2004-04-21
HUP0103017A3 (en)	2004-05-28
CN1545410A (zh)	2004-11-10
KR20040017326A (ko)	2004-02-26
PL365258A1 (en)	2004-12-27
DE60228968D1 (de)	2008-10-30
ZA200400481B (en)	2005-01-24
IL159841A0 (en)	2004-06-20
WO2003007926A2 (en)	2003-01-30
EA200400192A1 (ru)	2004-06-24
CZ200460A3 (cs)	2004-05-12
ATE408403T1 (de)	2008-10-15
HUP0103017A2 (hu)	2003-07-28

Publication	Publication Date	Title
RU2394570C2 (ru)	2010-07-20	Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
He et al.	2013	A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer'disease
DK2419104T3 (en)	2018-02-05	Combinations of 5-HT4 Receptor Agonists and Acetylcholinesterase Inhibitors to Treat Cognitive Disorders
WO2005009425A1 (de)	2005-02-03	Substituierte 2-aminotetraline zur behandlung von depressionen
Wu et al.	2003	Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice
EP4531850A1 (en)	2025-04-09	Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
Neugebauer et al.	2006	Effect of a novel nicotinic receptor antagonist, N, N′-dodecane-1, 12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats
UA78714C2 (en)	2007-04-25	Pharmaceutical composition for treating or preventing diseases involving decreasing and/or impaired cognitive functions
RU2493851C2 (ru)	2013-09-27	Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств
US20040044023A1 (en)	2004-03-04	Compositions and methods for treating or preventing memory impairment
GB2619119A (en)	2023-11-29	Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
EP2201950B1 (en)	2016-11-16	Compounds and methods for treating autism spectrum disorders
WO2007069925A2 (en)	2007-06-21	Non-neurotoxic recreational drugs and a method of treating recreational drug abuse
Kelly et al.	1999	An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression
TW202345789A (zh)	2023-12-01	精神作用醫藥及其用於治療精神及神經病狀及病症之用途
Vaglini et al.	2003	Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity in mice
AU2002317412A1 (en)	2003-03-03	Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions
JP4505410B2 (ja)	2010-07-21	モルヒネへの心理的依存又は耐性を防止及び処置するのに有効成分としてベルベリンを含有する医薬組成物
RU2784428C2 (ru)	2022-11-24	Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и мемантина
HK1069113A (en)	2005-05-13	Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
CA2390101A1 (en)	2001-05-17	A method of treating substance addiction
HK40071167A (en)	2022-11-04	Methods for treating behavioral and psychological symptoms in patients with dementia
Finberg et al.	2000	TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease
Martin et al.	1991	Antidepressant action of lithium gluconate alone and in co-administration with tricyclics in the learned helplessness paradigm in rats
HK1165722A (en)	2012-10-12	Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders